SeaStar Medical is trading at $2.08, down -5.02%, with no identified explanation for the decline. - As of 11:38 a.m. EST on November 3, 2026; the provided price context lists the prior close at $2.19. - On November 3, the FDA confirmed QUELIMMUNE’s pediatric SAVE Registry met post-approval study requirements. - The confirmation removes the registry research-infrastructure requirement for hospitals. This positive company news does not explain the current decline.